Search research articles
Contact Us
Filters
Showing results (91-100 of 115) with videos related to
Page
of 12
Sort By:
European Journal of Preventive Cardiology
|
September 6, 2017
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
Suzanne V Arnold, Silvio E Inzucchi, Fengming Tang, et al.
Frontiers in Endocrinology
|
May 9, 2022
Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study
Marília B Gomes, Fengming Tang, Hungta Chen, et al.
Circulation
|
February 8, 2021
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial
Michael E Nassif, Mohammed Qintar, Sheryl L Windsor, et al.
Clinical Cardiology
|
October 14, 2015
Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry
Seth S Martin, Kamil F Faridi, Parag H Joshi, et al.
American Heart Journal
|
July 18, 2018
Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)
Suzanne V Arnold, Justin B Echouffo-Tcheugui, Carolyn S P Lam, et al.
Diabetes Research and Clinical Practice
|
February 3, 2022
Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study
Antonio Nicolucci, Hungta Chen, Andrew Cooper, et al.
Journal of the American College of Cardiology
|
December 3, 2014
Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry
Thomas M Maddox, William B Borden, Fengming Tang, et al.
Diabetes Research and Clinical Practice
|
June 13, 2020
Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study
Wolfgang Rathmann, Bernard Charbonnel, Marília B Gomes, et al.
BMJ Open Diabetes Research & Care
|
May 4, 2021
Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
Brenda Bongaerts, Suzanne V Arnold, Bernard H Charbonnel, et al.
Diabetes, Obesity & Metabolism
|
September 16, 2022
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study
Bernard H Charbonnel, Hungta Chen, Javier Cid-Ruzafa, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 115) with videos related to
Sort By:
Page
of 12
European Journal of Preventive Cardiology
|
September 6, 2017
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
Suzanne V Arnold, Silvio E Inzucchi, Fengming Tang, et al.
Frontiers in Endocrinology
|
May 9, 2022
Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study
Marília B Gomes, Fengming Tang, Hungta Chen, et al.
Circulation
|
February 8, 2021
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial
Michael E Nassif, Mohammed Qintar, Sheryl L Windsor, et al.
Clinical Cardiology
|
October 14, 2015
Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry
Seth S Martin, Kamil F Faridi, Parag H Joshi, et al.
American Heart Journal
|
July 18, 2018
Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)
Suzanne V Arnold, Justin B Echouffo-Tcheugui, Carolyn S P Lam, et al.
Diabetes Research and Clinical Practice
|
February 3, 2022
Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study
Antonio Nicolucci, Hungta Chen, Andrew Cooper, et al.
Journal of the American College of Cardiology
|
December 3, 2014
Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry
Thomas M Maddox, William B Borden, Fengming Tang, et al.
Diabetes Research and Clinical Practice
|
June 13, 2020
Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study
Wolfgang Rathmann, Bernard Charbonnel, Marília B Gomes, et al.
BMJ Open Diabetes Research & Care
|
May 4, 2021
Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
Brenda Bongaerts, Suzanne V Arnold, Bernard H Charbonnel, et al.
Diabetes, Obesity & Metabolism
|
September 16, 2022
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study
Bernard H Charbonnel, Hungta Chen, Javier Cid-Ruzafa, et al.
Page
of 12